Guselkumab
生产企业：Janssen Biotech, Inc., Johnson & Johnson
Guselkumab is a monoclonal antibody used to treat moderate to severe plaque psoriasis.
Guselkumab is a monoclonal antibody used to treat moderate to severe plaque psoriasis.
Guselkumab targets the p19 alpha subunit of IL-23. While IL-23 promotes the normal inflammatory and immune responses, the p19 and p40 subunits of IL-23 are found to be over-expressed in the condition of psoriasis and other autoimmune inflammatory skin diseases . Guselkumab selectively binds to the p19 subunit of IL-23 in dendritic cells and keratinocytes and blocks its interaction with IL-23 receptor, which further prevents the release of other pro-inflammatory cytokines and chemokines via stimulation of immune cells such as Th17 cells . Thus, guselkumab blocks the abnormally-heightened signalling of inflammatory cascades that promote epidermal abnormalities including keratinocyte hyperproliferation and psoriatic plaque formation .
Indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, and for the treatment of adults with active psoriatic arthritis.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
